Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 33

1.

The State of the Absorb Bioresorbable Scaffold: Consensus From an Expert Panel.

Bangalore S, Bezerra HG, Rizik DG, Armstrong EJ, Samuels B, Naidu SS, Grines CL, Foster MT, Choi JW, Bertolet BD, Shah AP, Torguson R, Avula SB, Wang JC, Zidar JP, Maksoud A, Kalyanasundaram A, Yakubov SJ, Chehab BM, Spaedy AJ, Potluri SP, Caputo RP, Kondur A, Merritt RF, Kaki A, Quesada R, Parikh MA, Toma C, Matar F, DeGregorio J, Nicholson W, Batchelor W, Gollapudi R, Korngold E, Sumar R, Chrysant GS, Li J, Gordon JB, Dave RM, Attizzani GF, Stys TP, Gigliotti OS, Murphy BE, Ellis SG, Waksman R.

JACC Cardiovasc Interv. 2017 Dec 11;10(23):2349-2359. doi: 10.1016/j.jcin.2017.09.041. Review.

2.

Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.

Nissen SE, Yeomans ND, Solomon DH, Lüscher TF, Libby P, Husni ME, Graham DY, Borer JS, Wisniewski LM, Wolski KE, Wang Q, Menon V, Ruschitzka F, Gaffney M, Beckerman B, Berger MF, Bao W, Lincoff AM; PRECISION Trial Investigators.

N Engl J Med. 2016 Dec 29;375(26):2519-29. doi: 10.1056/NEJMoa1611593. Epub 2016 Nov 13.

3.

Infection with the Lyme disease pathogen suppresses innate immunity in mice with diet-induced obesity.

Zlotnikov N, Javid A, Ahmed M, Eshghi A, Tang TT, Arya A, Bansal A, Matar F, Parikh M, Ebady R, Koh A, Gupta N, Song P, Zhang Y, Newbigging S, Wormser GP, Schwartz I, Inman R, Glogauer M, Moriarty TJ.

Cell Microbiol. 2017 May;19(5). doi: 10.1111/cmi.12689. Epub 2016 Nov 25.

4.

When should fractional flow reserve be performed to assess the significance of borderline coronary artery lesions: Derivation of a simplified scoring system.

Matar FA, Falasiri S, Glover CB, Khaliq A, Leung CC, Mroue J, Ebra G.

Int J Cardiol. 2016 Nov 1;222:606-610. doi: 10.1016/j.ijcard.2016.07.171. Epub 2016 Aug 2.

PMID:
27517648
5.

Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease.

Ellis SG, Kereiakes DJ, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, Litt MR, Kini A, Kabour A, Marx SO, Popma JJ, McGreevy R, Zhang Z, Simonton C, Stone GW; ABSORB III Investigators.

N Engl J Med. 2015 Nov 12;373(20):1905-15. doi: 10.1056/NEJMoa1509038. Epub 2015 Oct 12.

6.

Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial.

Kereiakes DJ, Yeh RW, Massaro JM, Driscoll-Shempp P, Cutlip DE, Steg PG, Gershlick AH, Darius H, Meredith IT, Ormiston J, Tanguay JF, Windecker S, Garratt KN, Kandzari DE, Lee DP, Simon DI, Iancu AC, Trebacz J, Mauri L; Dual Antiplatelet Therapy (DAPT) Study Investigators.

JAMA. 2015 Mar 17;313(11):1113-21. doi: 10.1001/jama.2015.1671. Erratum in: JAMA. 2015 Jun 2;313(21):2185. JAMA. 2016 Jul 5;316(1):105. JAMA. 2016 Jul 5;316(1):105.

7.

Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.

Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR Jr, Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM; DAPT Study Investigators.

N Engl J Med. 2014 Dec 4;371(23):2155-66. doi: 10.1056/NEJMoa1409312. Epub 2014 Nov 16.

8.

A controlled trial of renal denervation for resistant hypertension.

Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL; SYMPLICITY HTN-3 Investigators.

N Engl J Med. 2014 Apr 10;370(15):1393-401. doi: 10.1056/NEJMoa1402670. Epub 2014 Mar 29.

10.

Effects of dalcetrapib in patients with a recent acute coronary syndrome.

Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS; dal-OUTCOMES Investigators.

N Engl J Med. 2012 Nov 29;367(22):2089-99. doi: 10.1056/NEJMoa1206797. Epub 2012 Nov 5.

11.

The management of thrombotic lesions in the cardiac catheterization laboratory.

Matar F, Mroue J.

J Cardiovasc Transl Res. 2012 Feb;5(1):52-61. doi: 10.1007/s12265-011-9327-6. Epub 2011 Oct 21. Review.

PMID:
22015675
13.

Renal dysfunction in heart failure is due to congestion but not low output.

Guglin M, Rivero A, Matar F, Garcia M.

Clin Cardiol. 2011 Feb;34(2):113-6. doi: 10.1002/clc.20831.

14.

Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease.

Rosenson RS, Elliott M, Stasiv Y, Hislop C; PLASMA II Investigators.

Eur Heart J. 2011 Apr;32(8):999-1005. doi: 10.1093/eurheartj/ehq374. Epub 2010 Nov 16.

PMID:
21081550
15.

A randomized controlled trial of angiography versus intravascular ultrasound-directed bare-metal coronary stent placement (the AVID Trial).

Russo RJ, Silva PD, Teirstein PS, Attubato MJ, Davidson CJ, DeFranco AC, Fitzgerald PJ, Goldberg SL, Hermiller JB, Leon MB, Ling FS, Lucisano JE, Schatz RA, Wong SC, Weissman NJ, Zientek DM; AVID Investigators.

Circ Cardiovasc Interv. 2009 Apr;2(2):113-23. doi: 10.1161/CIRCINTERVENTIONS.108.778647. Epub 2009 Feb 20.

PMID:
20031704
16.

Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome.

Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Shah PK, Tardif JC, Chaitman BR, Duttlinger-Maddux R, Mathieson J; dal-OUTCOMES Committees and Investigators.

Am Heart J. 2009 Dec;158(6):896-901.e3. doi: 10.1016/j.ahj.2009.09.017.

PMID:
19958854
17.

Limitations of embolic protection in saphenous vein graft intervention: insights from 202 consecutive patients.

Matar FA, Smith K, Rossi P, Vandormael M, Sullebarger JT, Taylor M, Caruncho C, Ali T, Kerensky R.

J Interv Cardiol. 2009 Jun;22(3):240-6. doi: 10.1111/j.1540-8183.2009.00465.x. Epub 2009 Apr 14.

PMID:
19490353
18.

Structure/function relationships in dyes for solar energy conversion: a two-atom change in dye structure and the mechanism for its effect on cell voltage.

O'Regan BC, Walley K, Juozapavicius M, Anderson A, Matar F, Ghaddar T, Zakeeruddin SM, Klein C, Durrant JR.

J Am Chem Soc. 2009 Mar 18;131(10):3541-8. doi: 10.1021/ja806869x.

PMID:
19275259
19.

Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial.

Rosenson RS, Hislop C, McConnell D, Elliott M, Stasiv Y, Wang N, Waters DD; PLASMA Investigators.

Lancet. 2009 Feb 21;373(9664):649-58. doi: 10.1016/S0140-6736(09)60403-7. Erratum in: Lancet. 2009 May 9-2009 May15;373(9675):1606. Lancet.2011 Apr 30;377(9776):1494.

PMID:
19231633
20.

Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial.

Nissen SE, Nicholls SJ, Wolski K, Rodés-Cabau J, Cannon CP, Deanfield JE, Després JP, Kastelein JJ, Steinhubl SR, Kapadia S, Yasin M, Ruzyllo W, Gaudin C, Job B, Hu B, Bhatt DL, Lincoff AM, Tuzcu EM; STRADIVARIUS Investigators.

JAMA. 2008 Apr 2;299(13):1547-60. doi: 10.1001/jama.299.13.1547. Epub 2008 Apr 1.

PMID:
18387931

Supplemental Content

Loading ...
Support Center